Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
NCYT should take all it's products to the US of A....they will lap it up in abundance there...it's not a conservative market place there and currently less bent than the UK.....I would be happy to see 50% of NCYTs cash reserve spent on a sales team there with distributors in all four corners served by a central NCYT warehousing hub.....x5 the market size and a very eager market place...the only caution there is protecting your products IP.
I read about a year ago a fair bit and I see a lot of medical professional whom have the same opinion.
"In April 2020, Rick Bright, who was removed as head of the Biomedical Advanced Research and Development Authority (BARDA) before the approval of the drug, submitted a whistleblower complaint asserting that Ridgeback pressured BARDA to provide funding to manufacture EIDD-2801 despite Bright's concerns that similar drugs in its class have mutagenic properties. A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it over similar concerns"
@Wilson,
Agreed BYP and his acolytes are FUD* specialists.
It's not even reasonable questioning, just pure contradiction on every level. They are here to spread Fear, Uncertainty and Doubt*
It's actually quite tiring, maybe that's part of the plan too :-(
if you read it, it's non COVID diagnostics and genomics testing across all therapy areas; cancer, cardio, respiratory, haemo etc...and also, vulnarable groups where vaccines have little effect.
"The Covid-19 pandemic has highlighted the importance of diagnostic services and endemic Covid-19 has further increased the need for significantly more capacity"
"The Covid-19 pandemic has further driven the need for change and demonstrated the importance of diagnostics in a modern, patient-centred health service."
"New diagnostic technologies should be rapidly evaluated – e.g. near-patient virus testing for Covid-19, advanced genomic technologies, artificial intelligence in imaging and endoscopy and wearables. The process for introducing these technologies should be further developed and communicated, with the roles of MHRA, NICE, CQC, the National Screening Committee, NHS Digital, NHSX and commissioners made clear. The Accelerated Access Collaborative could support coordination of this activity"
"The number of genomic scientists and medics should be expanded and developed in line with the national genomic programme requirements, especially in cancer. The broader healthcare workforce should be developed to respond to the increased use of genomics"
"Genomics: Activity is forecast to expand significantly over the next five years to meet the NHS Long Term Plan commitments, including more comprehensive cancer genomic testing and the introduction of whole genome sequencing"
"Genomic testing will be important in the response to Covid-19. This will include sequencing the virus to support identification of Covid-19 outbreaks and to better understand its effects on different patient groups"
TESTING IN ALL TREATMENT AREAS IS HERE TO STAY FOR A VERY LONG TIME !
Once you light the fuse with distributors like Victory Scientific in USA, other distributors follow much quicker than Europe, especially with new innovation ..and also with NCYT exhibiting in Atlanta is perfect timing.....market size is x5 the UK...I just hope they have enough product to supply the demand....:-)
It's good to see Victory Scientific already keen to want it.
This more than last, FLUs/ RSVs are going to be as bigger threat to the population as SARs. The need to differentiate will be important to determine treatment protocols.
https://www.victoryscientific.com/winterplex
when the volumes are low... it's doesn't take much to grind it down, especially the sentiment of a few thousand disgruntled individuals.... but that's ok.... for me there's 2-3 reasons to sell and 7 reasons to stay or buy ;-)
Philipishere,
You're not wrong with the information e.g with the DHSC dispute:
A LTH would list the pro/cons over the longer term and see if the DHSC dispute risk is outweighed by the potential e.g fundamentals (cash in bank, EBIDTA etc) , forwards sales, contracts e.g. WHO/ UNICEF, NHS open framework, product launches, IUP, USA footprint and sales potential, deeper research etc...and then make his /her up to sell or not.
A STH would use the DHSC dispute to create more fear, uncertainty, and doubt (FUD) volatility and cash gain on peoples fears and FOMO selling...daily up/down movement profit.
Both of the above is trading and what makes the market place....you just need to decide, what kind of trader are you?....you could be a bit of both?
iis want certainty and short term holders are trying their best to create uncertainty and volatility......NCYTs fundamentals are a certainty for at least the next couple years.....and after that, it would have been sold off anyway ;-)
as soon as the iis get wind or whiff of a buyer, they'll be on it like a hot potato....they know the contracts are there....IMO, the buyers are there, but not the right buyer and price ;-).....once the two match, that's when the rockets will fly.....also, once a formal announcement is made for a huge tender like Amazon is made, that too will attracked their interest....the DHSC dispute means nothing to the iis or the buyer, other than an opportunity to eventually buying at a slight discount.
I sometimes wonder if BoJo is hoping the NHS will fail, to support his push for need for privatisation message and sell off......:-l